U.S. Office REITs Stock News

Recent attention on Medtronic (MDT) has centered on two fresh catalysts: a partnership with Precision Neuroscience to link brain activity data with surgical navigation tools, and FDA 510(k) clearance for its connected MiniMed Go diabetes system. See our latest analysis for Medtronic. Those neurosurgery and diabetes updates come as Medtronic’s share price sits at US$98.74, with a 3.9% 90 day share price return and a 19.3% 1 year total shareholder return. This suggests momentum has been...

Wave Life Sciences recently outlined its 2026 priorities at the 44th Annual J.P. Morgan Healthcare Conference, emphasizing accelerated development of obesity candidate WVE-007, expansion of its RNA editing pipeline, and upcoming trials and regulatory filings across obesity, liver disease, and genetic disorders. A key highlight for investors was early WVE-007 data suggesting fat loss on par with GLP-1 therapies while preserving muscle, alongside planned multidose and add-on incretin trials...

Lindsay (LNN) shares have been reacting to the company’s first quarter earnings, which showed sales of US$155.82 million and net income of US$16.52 million, both below the comparable period last year. See our latest analysis for Lindsay. The recent first quarter results, along with a reaffirmed quarterly dividend and a new Chief Accounting Officer, come as Lindsay’s share price sits at US$124.72. The 7 day share price return is 5.21%, while the 1 year total shareholder return shows a 3.43%...

Understanding what is moving SiriusPoint shares SiriusPoint (SPNT) has stayed on investors’ radars after mixed recent returns, with a gain over the past 3 months but declines over the past month and year to date prompting closer attention. See our latest analysis for SiriusPoint. The latest share price of $20.17 sits alongside a 30 day share price return of a 9.63% decline and a 90 day share price return of a 13.63% gain. The 1 year total shareholder return of 36.38% and 3 year total...

Dillard's stock performance snapshot Dillard's (DDS) has drawn investor interest after a mixed return profile, with a 1 day decline of 7.4% and a month pullback of 4.4%, alongside a 1 year total return of 49.7%. See our latest analysis for Dillard's. The recent 7.4% one day share price decline and softer 1 month share price return sit against a much stronger backdrop, with the 1 year total shareholder return close to 50% and the 5 year total shareholder return above 10x. If Dillard's recent...

Interest in Philip Morris International (PM) has picked up as investors react to recent fund commentary on its reduced risk products and look ahead to the company’s upcoming Q4 2025 earnings and dividend story. See our latest analysis for Philip Morris International. The stronger interest in reduced risk products and the upcoming Q4 2025 earnings update has coincided with a clear pickup in momentum, with a 1 month share price return of 8% and a 1 year total shareholder return of 49.46% from a...

Context for D-Wave Quantum’s recent stock moves D-Wave Quantum (QBTS) has drawn investor attention after a recent stretch of mixed returns, with a gain over the month but weaker performance over the past 3 months. This has prompted closer scrutiny of its fundamentals. The company operates in quantum computing systems and services, and recent price swings are being weighed against its current revenue base, ongoing losses, and growth metrics as investors reassess risk and potential reward. See...

Wondering whether Amazon.com’s share price still makes sense after its long run as a market favorite? This article walks you through what that current price could imply about value. The stock last closed at US$236.65, with a 3.9% decline over 7 days, a 6.3% gain over 30 days, and returns of 4.5% year to date, 7.2% over 1 year, 152.6% over 3 years, and 43.1% over 5 years. Recent headlines around Amazon.com have focused on its ongoing expansion across e commerce and cloud services, as well as...

Li Auto Inc. reported past operating results for December and full-year 2025, disclosing deliveries of 44,246 vehicles for the month, 109,194 for the quarter, and about 1.54 million for the year. The scale of these deliveries underscores how central monthly and annual volume data have become for assessing Li Auto’s execution and demand profile. We’ll now examine how Li Auto’s approximately 1.54 million full-year 2025 deliveries may influence the company’s existing investment narrative. The...

Earlier this month, Realty Income announced its 667th consecutive monthly dividend of US$0.2700 per share, payable on February 13, 2026 to shareholders of record on January 30, 2026. The company also unveiled a long-term partnership with GIC, including a US$1.50 billions logistics joint venture and its first industrial investment in Mexico via a roughly US$200 million build-to-suit portfolio. We’ll now examine how the GIC logistics joint venture and Mexico expansion could influence Realty...

If you are wondering whether KBR's current share price reflects its true worth, you are not alone. Many investors are asking the same question. The stock last closed at US$44.02, with returns of 4.2% over 7 days, 2.2% over 30 days, 8.7% year to date, a 25.1% decline over 1 year, a 8.5% decline over 3 years, and a 47.7% gain over 5 years. Recent news around KBR has highlighted ongoing interest in its role within the commercial services and engineering space, keeping attention on how its...

Earlier this month, Kiniksa Pharmaceuticals International presented at the 44th Annual J.P. Morgan Healthcare Conference and later reported that ARCALYST’s adoption as a second-line treatment for recurrent pericarditis underpinned its projection of US$900 million to US$920 million in net product revenue for 2026, supported by a cash balance of US$414.1 million and no debt. The company also highlighted pipeline progress, including the ongoing Phase 2/3 trial for KPL-387 with data expected in...

Arcellx (ACLX) is back in focus after reporting Phase 2 data for its anitocabtagene autoleucel therapy in relapsed or refractory multiple myeloma, which showed a 96% overall response rate and a 74% complete response rate. See our latest analysis for Arcellx. The latest anitocabtagene autoleucel update comes after a mixed stretch for Arcellx, with a 7 day share price return of 7.46% and a 90 day share price return decline of 21.37%, while the 3 year total shareholder return of 119.69% points...

Melco Resorts & Entertainment previously announced that, effective April 1, eligible non-management employees in Macau would receive pay rises ranging from 2% to 6.3%, with full-time staff earning up to MOP$16,000 per month getting a fixed increment and higher earners receiving a 2% increase. The move highlights management’s focus on employee retention and workforce stability in Macau’s competitive hospitality market, which can be an important consideration for long-term operational...

Event context and recent return snapshot Innovex International (INVX) has attracted fresh attention after recent trading moves, with the stock showing a 1 day return of about a 1% decline, alongside gains over the past week, month, and past 3 months. See our latest analysis for Innovex International. That short term pullback sits against a stronger backdrop, with a 90 day share price return of 36.71% and a 1 year total shareholder return of 40.27%. This points to momentum building rather than...

eBay (EBAY) has been drawing attention after a recent stretch of gains, with the share price up 4.7% over the past week and about 14% over the past month. This performance has prompted fresh interest in its current valuation. See our latest analysis for eBay. Zooming out, the recent 14.3% 1 month share price return builds on steadier gains, with an 8.5% year to date share price return and a 47.2% 1 year total shareholder return. This hints that momentum has been strengthening rather than...

KBK exit puts Main Street Capital’s investment approach in focus Main Street Capital (MAIN) recently exited its long running debt and equity investments in KBK Industries after the business was sold to a buyer, realizing a gain and internal rate of return on the position. For you as a shareholder or prospective investor, this kind of outcome highlights how a single portfolio exit can affect realized results, portfolio recycling, and the way a business development company’s stock may be...

Earlier this week, Qiagen N.V. outlined its 2026 priorities at the J.P. Morgan Healthcare Conference and the German Investment Seminar, following a special US$2.29 cash dividend with an ex-dividend date of January 8, 2026. The company underscored plans to expand its five core growth pillars, integrate the Parse Biosciences acquisition for single-cell analysis, and pursue automation, AI, and targeted M&A to reach a combined US$2.00 billion in pillar sales by 2028. We’ll now examine how...

Earlier in January 2026, Apogee Therapeutics reported positive interim Phase 1b data for its half-life extended anti-IL-13 antibody zumilokibart (APG777) in mild-to-moderate asthma, showing a favorable safety profile and strong, durable FeNO suppression after a single 720 mg dose. The update also outlined an ambitious 2026 clinical roadmap for zumilokibart and combination asset APG279 across atopic dermatitis and broader immunology indications, underscoring Apogee’s push to build a...

Coherent (COHR) just rolled out its WaveShaper 1000A Sharp, a programmable optical filter with roughly double the frequency resolution of prior tools, drawing fresh investor attention to the stock and its communications exposure. See our latest analysis for Coherent. The WaveShaper launch and a string of AI data center and telecom focused announcements come after a very strong 90 day share price return of 58.77%. Coherent’s 1 year total shareholder return of 90.89% and 3 year total...

Kennametal recently delivered an earnings report with year-on-year revenue growth, organic strength, and higher full-year guidance, while analysts have responded with upgraded views on its earnings potential tied to tungsten price movements. An unusual spike in tungsten prices is now a central factor for Kennametal, as some analysts see it meaningfully influencing margins and near-term earnings quality. We’ll now examine how stronger earnings, upgraded guidance, and tungsten-driven margin...

Why Albany International Stock Is Back on Investors’ Radar A proposed US$1.5 trillion defense budget for 2027 has pushed investors toward industrial and defense related names, putting Albany International (AIN) in focus as part of this broader sector rotation. See our latest analysis for Albany International. Albany International’s share price has responded quickly to the proposed US$1.5 trillion defense budget, with a 9.17% 7 day share price return and 13.90% 30 day share price return...

If you are wondering whether CorMedix is starting to look mispriced after a rough stretch, this article walks through what the current share price might imply about its underlying value. The stock closed at US$7.09, with returns of a 36.5% decline over 7 days, a 37.4% decline over 30 days and a 41.7% decline year to date, set against a 60.8% gain over 3 years and a 19.8% decline over 5 years. Recent CorMedix headlines have focused on its progress and risks as a smaller pharmaceuticals and...

If you are wondering whether Brookfield Business Partners at around US$34.85 offers good value today, you are not alone. This article breaks down what that price could mean for long term investors. The unit price has moved 2.7% over the last week, while the 30 day return is a 0.9% decline and the 1 year return sits at 58.1%, with a 3 year return of 91.5% and 5 year return of 42.7%. Recent attention on Brookfield Business Partners has centered on its position as a listed arm of the wider...